MINYANVILLE ORIGINAL Aegerion Pharmaceuticals (NASDAQ:AEGR) has won US approval to sell a drug that treats a rare genetic condition linked to heart disease in young people. Aegerion’s cholesterol-lowering capsule drug Juxtapid was approved by the Food and Drug Administration to help fight homozygous familial hypercholesterolemia. It’s the first drug approved for the money-losing biotech company. The medicine is aimed at a small patient population. Initially Aegerion estimates about 3 000 patients in the US can be treated with the product CEO Marc Beer says. Beer told analysts on a conference call Monday morning that Juxtapid will be priced between ...